Neurosterix Closes $105M Series B; Addex Stake Diluted to 8.5%
ADXN is trading near its 52-week low of $2.56 (13% above the low).
Summary
Addex's spin-out Neurosterix closed a $105 million Series B from a syndicate of life science investors. Addex did not put money in, so its stake fell from 20% to 8.5% of Neurosterix, now carried at an $18.6 million valuation. The cash is earmarked mainly for Phase 2 development of NTX-253, the M4 PAM for schizophrenia that cleared Phase 1, plus the broader neuropsychiatric pipeline. For a company with a roughly $3.3 million market cap that flagged going-concern doubt in its H1 report, an $18.6 million stake in a well-funded private asset is the bulk of the story — it is a mark-to-market gain on the balance sheet, not cash in Addex's hands. The dilution of the ownership percentage is the trade-off; Addex keeps upside through the smaller stake but no longer controls the program's financing.
At the time of this announcement, ADXN was trading at $2.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $2.56 to $11.97. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.